Xenetic Biosciences Inc Asset Resilience Ratio
Xenetic Biosciences Inc asset resilience ratio. Xenetic Biosciences Inc (XBIO) has an Asset Resilience Ratio of 0.43% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Xenetic Biosciences Inc (XBIO) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xenetic Biosciences Inc (2014–2017)
Asset resilience ratio of Xenetic Biosciences Inc from 2014 to 2017. This chart shows how Xenetic Biosciences Inc's Asset Resilience Ratio has changed over time. Read XBIO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Xenetic Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XBIO total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.00K | 0.43% |
| Total Liquid Assets | $67.00K | 0.43% |
Asset Resilience Insights
- Limited Liquidity: Xenetic Biosciences Inc maintains only 0.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Xenetic Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Xenetic Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Xenetic Biosciences Inc Asset Resilience Ratio by Year (2014–2017)
Xenetic Biosciences Inc asset resilience ratio by year from 2014 to 2017. The table below shows the annual Asset Resilience Ratio data for Xenetic Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.35% | $67.00K | $19.16 Million | +0.03pp |
| 2016-12-31 | 0.32% | $67.00K | $20.97 Million | -0.08pp |
| 2015-12-31 | 0.40% | $67.00K | $16.91 Million | -0.01pp |
| 2014-12-31 | 0.40% | $66.00K | $16.32 Million | -- |
About Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatmen… Read more